PUMA BIOTECHNOLOGY, INC. (PBYI) Overview
- 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 0.16; Beat / miss (m).
- 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.07; Beat / miss (m).
- 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.17; Beat / miss (m).
- 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 0.12; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $8.24
- Previous close
- $9.78
- Change
- -$1.54
- Change (%)
- -15.75%
- Close date
- 2026-11-06
- Previous close date
- 2026-09-29
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- PBYI
- +64.37%
- S&P 500
- (m)
1 year
- PBYI
- +93.66%
- S&P 500
- (m)
3 years
- PBYI
- +271.86%
- S&P 500
- (m)
5 years
- PBYI
- +39.12%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
30 Jun 2026 ○ Estimate (m) ● Actual 0.16
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Apr 2026 | 30 Jun 2026 | (m) | 0.16 | (m) | (m) |
| 1 Jan 2026 | 31 Mar 2026 | (m) | -0.07 | (m) | (m) |
| 1 Jul 2025 | 30 Sept 2025 | (m) | 0.17 | (m) | (m) |
| 1 Apr 2025 | 30 Jun 2025 | (m) | 0.12 | (m) | (m) |
| 1 Jan 2025 | 31 Mar 2025 | (m) | 0.06 | (m) | (m) |
31 Dec 2025 ○ Estimate (m) ● Actual 0.61
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2025 | 31 Dec 2025 | (m) | 0.61 | (m) | (m) |
| 1 Jan 2024 | 31 Dec 2024 | (m) | 0.62 | (m) | (m) |
| 1 Jan 2023 | 31 Dec 2023 | (m) | 0.45 | (m) | (m) |
| 1 Jan 2022 | 31 Dec 2022 | (m) | 0.00 | (m) | (m) |
| 1 Jan 2021 | 31 Dec 2021 | (m) | -0.72 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
30 Jun 2026 ■ Revenue 56.50M ■ Earnings 8.19M — Profit margin 14.49%
31 Dec 2025 ■ Revenue 228.37M ■ Earnings 31.11M — Profit margin 13.62%
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $8.24 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning PBYI
View more →(m)
Statistics
View more →Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $26.72M
- Profit margin
- 11.55%
- Return on assets · 12 month
- 13.78%
- Index membership
- (m)
- Employees
- 172.00
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 306.80K
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- -0.41%*
- Total return · month
- 7.95%*
- Total return · quarter
- 19.41%*
- Total return · half year
- 60.86%*
- Total return · year to date
- 64.37%*
- Total return · 1 year
- 93.66%*
- Total return · 3 years
- 271.86%*
- Total return · 5 years
- 39.12%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- Revenue · 12 month
- $231.24M
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- 0.00%*
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
PUMA BIOTECHNOLOGY, INC. Overview
View more →(m)
(m)
- SEC CIK
- 1401667
- Industry (SIC)
- 2834 Pharmaceutical Preparations
- Country of operation
- United States
- Business address
- 10880 WILSHIRE BLVD., SUITE 1700, LOS ANGELES, California, United States
- Fiscal year end
- 1231
- Phone
- (424) 248-6500
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |